Background: The 1-min sit-to-stand test (1STST) is a practical tool to evaluate physical capacity. The aim of this study was to assess the impact of tezacaftor and ivacaftor on functional exercise capacity, muscle strength and symptoms in people with ...
Aubriot Anne-Sophie +6 more
doaj +1 more source
Co‐Design of a Novel Telehealth Exercise Model of Care for Adults With Cystic Fibrosis
Pediatric Pulmonology, Volume 61, Issue 3, March 2026.
Megan Poulsen +3 more
wiley +1 more source
Editorial: Real-world experience with CFTR modulator therapy
Burkhard Tümmler +3 more
doaj +1 more source
Towards personalized medicine in cystic fibrosis:Focusing on clinical pharmacology of CFTR modulators [PDF]
This thesis aimed to improve understanding of the clinical pharmacology of CFTR modulators in children with cystic fibrosis (CF) using real-world data, thereby supporting progress towards personalized medicine.To enable pharmacokinetic analyses, two ...
Vonk, S.E.M.
core +2 more sources
The monogenic rare disease Cystic Fibrosis (CF) is caused by mutations in the gene encoding the CF transmembrane conductance (CFTR) protein, an anion channel expressed at the apical plasma membrane of epithelial cells.
Filipa C. Ferreira +2 more
doaj +1 more source
Standards for the care of people with cystic fibrosis; establishing and maintaining health [PDF]
Cystic fibrosis; Health; StandardsFibrosis quística; Salud; EstándaresFibrosi quística; Salut; EstàndardsThis is the second in a series of four papers updating the European Cystic Fibrosis Society (ECFS) standards for the care of people with CF.
Addy, Charlotte +31 more
core +4 more sources
Ion channel expression in human melanoma samples. in silico identification and experimental validation of molecular targets [PDF]
Expression of 328 ion channel genes was investigated, by in silico analysis, in 170 human melanoma samples and controls. Ninety-one members of this gene-family (i.e., about 28%) show a significant (p 0.90 and p 90% in most cases).
D’Arcangelo, Daniela +5 more
core +1 more source
Decline in HbA1c during the first year of elexacaftor/tezacaftor/ivacaftor treatment in the Danish cystic fibrosis cohort:Short title: Decline in HbA1c after elexacaftor/tezacaftor/ivacaftor treatment [PDF]
Background: Elexacaftor/tezacaftor/ivacaftor (ETI) has improved the clinical status of individuals with cystic fibrosis (CF), however, whether ETI impacts glucose tolerance remains unknown.
Almdal, Thomas Peter +10 more
core +1 more source
Tezacaftor is a direct inhibitor of sphingolipid delta-4 desaturase enzyme (DEGS) [PDF]
Background: We recently demonstrated that 48 h exposure of primary human bronchial epithelial (hBE) cells, obtained from both CF (F508del homozygous) and non-CF subjects, to the triple drug combination Elexacaftor/Tezacaftor/Ivacaftor (ETI) results in a ...
Armirotti, Andrea +14 more
core +1 more source

